abagovomab

BIOLOGICAL2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Menarini Group

Conditions

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer

Phase 1

Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

CompletedNCT00058435

Memorial Sloan Kettering Cancer CenterFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

Start: 2002-12-31End: 2004-03-31Updated: 2013-06-05

Phase 2

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients

TerminatedNCT00418574

Menarini GroupOvarian Cancer

Start: 2006-12-31End: 2011-06-30Updated: 2011-11-24

Related Papers

373 Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer

Ovarian cancer2020-12-011 citations

A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients.

2017-09-1418 citations

Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.

2014-06-2116 citations